MYOS RENS Technology to Present at the MicroCap Conference April 10 in New York City at the Essex House

CEDAR KNOLLS, N.J., April 3, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the natural product that helps build lean muscle in conjunction with resistance training, announced that the Company's Chief Executive Officer, Joseph Mannello, will present at the MicroCap Conference on Tuesday, April 10th at 12:30 p.m. Eastern Time at the Essex House in New York City. Mr. Mannello will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

"We are excited about the opportunity to meet with investors to discuss our recent business developments," said Mr. Mannello. "These include our growing portfolio of research projects to further explore the benefits of our proprietary ingredient, Fortetropin®; our new Fortetropin®-based pet product; and additional brand development initiatives that position us to tap into the $28 billion-and-rising fitness and sports nutrition market, as well as the active senior population which is expected to double over the next 30 years."

To request free registration, please go to the conference website (https://microcapconf.com/), and click the "Registration" button.

About MYOS RENS Technology Inc.

MYOS RENS Technology Inc. (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin® has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin® has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.MYOSRENS.com.

 

Back to news